当前位置:首页 > 试剂知识 > 新闻公告 > 艾科试剂:Pathway-Specific Remodeling of Thalamostriatal Synapses

艾科试剂:Pathway-Specific Remodeling of Thalamostriatal Synapses


 
来源:http://www.aikeshiji.com
By : 艾科试剂   |  2016-02-14

Philip R.L. Parker, Arnaud L. Lalive, Anatol C. Kreitzer

 

Movement suppression in Parkinson’s disease (PD) is thought to arise from increased efficacy of the indirect pathway basal ganglia circuit, relative to the direct pathway. However, the underlying pathophysiological mechanisms remain elusive. To examine whether changes in the strength of synaptic inputs to these circuits contribute to this imbalance, we obtained paired whole-cell recordings from striatal direct- and indirect-pathway medium spiny neurons (dMSNs and iMSNs) and optically stimulated inputs from sensorimotor cortex or intralaminar thalamus in brain slices from control and dopamine-depleted mice. We found that dopamine depletion selectively decreased synaptic strength at thalamic inputs to dMSNs, suggesting that thalamus drives asymmetric activation of basal ganglia circuitry underlying parkinsonian motor impairments. Consistent with this hypothesis, in vivo chemogenetic and optogenetic inhibition of thalamostriatal terminals reversed motor deficits in dopamine-depleted mice. These results implicate thalamostriatal projections in the pathophysiology of PD and support interventions targeting thalamus as a potential therapeutic strategy.

 
 
以上资料由艾科试剂:http://www.aikeshiji.com提供
首页| 帮助中心| 网站使用条款| 隐私政策| 公司简介|

成都博瑞特化学技术有限公司  www.aikeshiji.com 艾科试剂版权所有

艾科试剂官方网址

蜀ICP备11026452号 危险品化学品经营许可证 电子营业执照

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或治疗,非药用,非食用。

川公网安备 51010402000086号